E Fund Management Co. Ltd. Has $334,000 Stake in Arcellx, Inc. (NASDAQ:ACLX)

E Fund Management Co. Ltd. decreased its holdings in shares of Arcellx, Inc. (NASDAQ:ACLX) by 26.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,012 shares of the company’s stock after selling 2,144 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Arcellx were worth $334,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Rafferty Asset Management LLC boosted its holdings in Arcellx by 10.2% during the third quarter. Rafferty Asset Management LLC now owns 158,778 shares of the company’s stock worth $5,697,000 after purchasing an additional 14,682 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Arcellx by 98.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,248 shares of the company’s stock worth $45,000 after purchasing an additional 619 shares during the last quarter. Vivo Capital LLC boosted its holdings in Arcellx by 16.1% during the third quarter. Vivo Capital LLC now owns 503,565 shares of the company’s stock worth $18,068,000 after purchasing an additional 69,780 shares during the last quarter. Swiss National Bank boosted its holdings in Arcellx by 21.5% during the third quarter. Swiss National Bank now owns 63,300 shares of the company’s stock worth $2,271,000 after purchasing an additional 11,200 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its holdings in Arcellx by 87.5% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 30,000 shares of the company’s stock worth $1,706,000 after purchasing an additional 14,000 shares during the last quarter. Institutional investors and hedge funds own 96.03% of the company’s stock.

Insider Activity at Arcellx

In other Arcellx news, insider Christopher Heery sold 2,967 shares of Arcellx stock in a transaction on Monday, February 12th. The stock was sold at an average price of $64.46, for a total value of $191,252.82. Following the completion of the transaction, the insider now directly owns 30,303 shares of the company’s stock, valued at approximately $1,953,331.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Arcellx news, insider Christopher Heery sold 2,967 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $64.46, for a total value of $191,252.82. Following the transaction, the insider now directly owns 30,303 shares of the company’s stock, valued at approximately $1,953,331.38. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jill Carroll sold 504,263 shares of the business’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $70.55, for a total transaction of $35,575,754.65. Following the completion of the transaction, the director now owns 1,479,148 shares of the company’s stock, valued at $104,353,891.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 620,526 shares of company stock worth $43,157,182. Company insiders own 6.24% of the company’s stock.

Arcellx Stock Up 0.9 %

Shares of Arcellx stock traded up $0.48 during trading on Thursday, reaching $52.73. The company’s stock had a trading volume of 377,239 shares, compared to its average volume of 447,280. The business’s 50-day moving average price is $62.18 and its 200-day moving average price is $56.72. Arcellx, Inc. has a 52 week low of $30.74 and a 52 week high of $75.10. The firm has a market cap of $2.81 billion, a PE ratio of -35.69 and a beta of 0.24.

Arcellx (NASDAQ:ACLX) last issued its quarterly earnings data on Wednesday, February 28th. The company reported $0.42 earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.95. Arcellx had a negative net margin of 64.08% and a negative return on equity of 20.96%. The business had revenue of $63.15 million during the quarter, compared to analysts’ expectations of $20.07 million. During the same quarter in the previous year, the company earned ($0.76) EPS. Equities analysts predict that Arcellx, Inc. will post -1.69 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on ACLX. HC Wainwright upped their price target on shares of Arcellx from $60.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, February 29th. Barclays upped their price target on shares of Arcellx from $62.00 to $73.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. Robert W. Baird upped their price target on shares of Arcellx from $63.00 to $77.00 and gave the stock an “outperform” rating in a research report on Thursday, February 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $81.00 price target on shares of Arcellx in a research report on Tuesday. Finally, Scotiabank reaffirmed an “outperform” rating and set a $82.00 price target on shares of Arcellx in a research report on Thursday, April 4th. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $75.64.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).